Financials in USD. Standardized financial statements.
A compact view of how Aida Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
|---|---|---|---|---|
| Revenue? | $29.20M | $29.64M | $24.53M | $15.64M |
| Revenue Growth? | -1.5% | +20.9% | +56.8% | 0.0% |
| Cost of Revenue? | $14.51M | $14.08M | $8.33M | $4.62M |
| Gross Profit? | $14.69M | $15.56M | $16.19M | $11.02M |
| Gross Margin? | +50.3% | +52.5% | +66.0% | +70.5% |
| Operating Expenses? | $9.25M | $11.63M | $14.07M | $8.17M |
| Operating Income? | $5.45M | $3.94M | $2.12M | $2.86M |
| EBITDA? | $7.32M | $6.02M | $3.81M | $3.63M |
| Income Before Tax | $2.02M | $2.32M | $1.51M | $2.54M |
| Income Tax Expense | $360,041 | $173,258 | $144,720 | $150,997 |
| Net Income? | $2.74M | $1.45M | $1.47M | $1.64M |
| EPS? | $0.10 | $0.06 | $0.06 | $0.07 |
| Diluted EPS? | $0.10 | $0.06 | $0.06 | $0.07 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality